

1 **Title:** Exposure to heavy metals *in utero* and autism spectrum disorder at age 3: A meta-
2 analysis of two longitudinal cohorts of siblings of children with autism
3

4 **Authors:** John F. Dou¹, Rebecca J. Schmidt², Heather E. Volk³, Manon M. Nitta¹, Jason I.
5 Feinberg³, Craig J. Newschaffer⁴, Lisa A. Croen⁵, Irva Hertz-Picciotto², M. Daniele Fallin⁶, Kelly
6 M. Bakulski¹
7

8 **Affiliations:**

9 ¹University of Michigan, Ann Arbor, Michigan, USA

10 ²University of California Davis, Davis, California, USA

11 ³Johns Hopkins University, Baltimore, Maryland, USA

12 ⁴Penn State University, State College, PA, USA

13 ⁵Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA

14 ⁶Rollins School of Public Health, Emory University, Atlanta, GA, USA
15
16

17 **Corresponding author:**

18 Kelly M. Bakulski, email: bakulski@umich.edu, phone: (734) 615 5899, address: M5511 SPH2,
19 1415 Washington Heights Ann Arbor, MI 48109
20

21 **Conflicts of Interest:** The authors declare they have no conflicts of interest related to this work
22 to disclose.
23

24 **Funding Acknowledgements:**

25 Funding for the EARLI study was provided by the National Institutes of Health (R01ES016443,
26 R24ES030893) and Autism Speaks (003953). Funding for the MARBLES study was provided by
27 the National Institutes of Health (R01ES020392, R01ES028089, R/U24ES028533, and
28 P01ES011269) and the United States Environmental Protection Agency Science to Achieve
29 Results program (#RD-83329201). Funding for metals measures and this work was supported
30 by the National Institutes of Health (R01ES025531). The content is solely the responsibility of
31 the authors and does not necessarily represent the official views of the National Institutes of
32 Health.

33 **Abstract**

34 **Background:** Autism spectrum disorder (ASD) is a prevalent and heterogeneous
35 neurodevelopmental disorder. Risk is attributed to genetic and prenatal environmental factors,
36 though the environmental agents are incompletely characterized.

37
38 **Methods:** In Early Autism Risk Longitudinal Investigation (EARLI) and Markers of Autism Risk
39 in Babies Learning Early Signs (MARBLES), two pregnancy cohorts of siblings of children with
40 ASD, maternal urinary metals concentrations at two time points during pregnancy were
41 measured using inductively coupled plasma mass spectrometry. At age three, clinicians
42 assessed ASD with DSM-5 criteria. Using multivariable log binomial regression, we examined
43 each metal for association with ASD status, adjusting for gestational age at urine sampling, child
44 sex, maternal age, and maternal education, and meta-analyzed across the two cohorts.

45
46 **Results:** In EARLI (n=170) 17.6% of children were diagnosed with ASD, and an additional
47 43.5% were classified as having other non-neurotypical development (Non-TD). In MARBLES
48 (n=156), 22.7% were diagnosed with ASD, while an additional 11.5% had Non-TD. In earlier
49 pregnancy metals measures, having cadmium concentration over the level of detection was
50 associated with 1.78 (1.19, 2.67) times higher risk of ASD, and 1.43 (1.06, 1.92) times higher
51 risk of Non-TD. A doubling of early pregnancy cesium concentration was marginally associated
52 with 1.81 (0.95, 3.42) times higher risk of ASD, and 1.58 (0.95, 2.63) times higher risk of Non-
53 TD.

54
55 **Conclusion:** Exposure *in utero* to elevated levels of cadmium and cesium, as measured in
56 maternal urine collected during pregnancy, was associated with increased risk of developing
57 ASD.

58
59 **Keywords:** Metals exposure, autism spectrum disorder, pregnancy cohort, epidemiology,
60 cadmium

61 Introduction

62 Autism Spectrum Disorder (ASD) presents a major public health concern. ASD is a
63 neurodevelopmental disorder characterized by impairments in social communication, social
64 interaction, and restrictive and repetitive behavioral patterns and interests (Diagnostic and
65 statistical manual of mental disorders □: DSM-5. 2013). In the United States, 1 in 36 children are
66 affected by ASD, with the prevalence among boys 3.8 times greater than among girls (Maenner
67 et al. 2023). Individuals with ASD and their families face significant social and financial burdens,
68 with higher costs for individuals with more severe ASD (Rogge and Janssen 2019). The social
69 cost of ASD was greater than \$7 trillion between the years 1990 – 2019 and is projected to be
70 an additional \$4 to \$15 trillion by 2029 (Cakir et al. 2020). Increases in ASD prevalence have
71 been attributed to increasing social awareness (Keyes et al. 2012), changes to diagnostic
72 criteria (Hansen et al. 2015), and participation in early intervention services (Worley et al. 2011).
73 However, the full source of this increase is largely unknown, suggesting incidence may be
74 rising. Environmental exposures may play a role in this increase. Understanding modifiable risk
75 factors for ASD could play a major role in guiding public health interventions.

76 Metals are a potential modifiable risk factor in ASD. In the United States, women of
77 childbearing age experience widespread environmental exposure to metals, and higher
78 concentrations have been observed in pregnant woman compared to non-pregnant women
79 (Martin and Fry 2018; Watson et al. 2020). Important neurodevelopmental processes occur
80 during pregnancy (Estes and McAllister 2016), and exposure to environmental factors such as
81 metals are suggested to have a role in ASD etiology (Bölte et al. 2019; Heyer and Meredith
82 2017; Lyall et al. 2014). Among children diagnosed with ASD relative to controls, higher blood
83 levels of arsenic (Ding et al. 2023), mercury (Ding et al. 2023; Jafari et al. 2017; Zhang et al.
84 2021), lead (Rashaid et al. 2021; Saghazadeh and Rezaei 2017; Zhang et al. 2021), and
85 cadmium (Baj et al. 2021) have been observed. Although these findings are suggestive,
86 exposure to metals was measured after ASD diagnosis. In studies where child levels of metals

87 were measured after ASD was diagnosed, it is not known if elevated exposure levels preceded
88 ASD. Some studies have examined exposure during pregnancy. Poorer performance on social
89 and behavioral tests among children at age 3 was associated with elevated manganese levels
90 in infant toenails and arsenic in maternal toenails (Doherty et al. 2020), and prenatal maternal
91 blood lead levels (Fruh et al. 2019). In contrast, elevated copper levels in maternal urine or
92 blood during pregnancy was associated with decreased behavior problems assessed in children
93 aged 3-7 years (Jedynak et al. 2021). Studies examining ASD diagnosis and metals exposure
94 during pregnancy are less common. One nested case-control study in the Norwegian Mother,
95 Father, and Child Cohort Study linked with the Norwegian Patient Registry examined maternal
96 blood metals concentrations during pregnancy, finding elevated arsenic, cadmium, and
97 manganese were associated with ASD, and lower levels of cesium, copper, mercury, and zinc
98 were associated with ASD (Skogheim et al. 2021). There is limited study on prenatal metals
99 exposure and ASD, and more prospective cohorts with exposure measures of multiple metals
100 are needed.

101 This study was conducted in two pregnancy cohorts of siblings of children with ASD, the
102 Early Autism Risk Longitudinal Investigation (EARLI) and the Markers of Autism Risk in Babies -
103 Learning Early Signs (MARBLES) study. The goal of this study was to examine the associations
104 between concentrations of a panel of twenty-two metals measured during pregnancy with ASD
105 diagnosis in children at age 3 years.

106

107 **Methods**

108 *Study sample*

109 The Early Autism Risk Longitudinal Investigation (EARLI) is a prospective pregnancy
110 cohort to study autism etiology (Newschaffer et al. 2012). The EARLI study was reviewed and
111 approved by Human Subjects Institutional Review Boards (IRBs) from each of the four study
112 sites (Johns Hopkins University, Drexel University, University of California Davis, and Kaiser

113 Permanente Northern California). Markers of Autism Risk Learning Early Signs (MARBLES) is
114 also an enriched-familial risk prospective pregnancy cohort to study autism etiology (Hertz-
115 Picciotto et al.). The MARBLES protocol was reviewed and approved by the Human Subjects
116 IRB from University of California Davis. Secondary data analysis for this manuscript was
117 approved by the Human Subjects IRB for the University of Michigan. These studies recruited
118 mothers of children with clinically confirmed ASD (probands) who were early in a subsequent
119 pregnancy or were trying to become pregnant. Siblings of children with ASD are more likely to
120 have a diagnosis of ASD or other developmental delays (Hansen et al. 2019; Miller et al. 2019).
121 In EARLI there were 232 mothers with a subsequent child (sibling) born during the study
122 between November 2009 and March 2012. In MARBLES there were 389 enrolled mothers that
123 gave birth to 425 subsequent children (sibling) between December 1, 2006 and July 1, 2016.

124

125 *Covariate and outcome assessment*

126 Demographics, pregnancy behaviors, and medical history were all collected via maternal
127 questionnaire at enrollment. For the children born during the study (siblings), at age three years
128 clinicians assessed them with DSM-5 criteria. Children were categorized into three groups:
129 typically developing, ASD, or other non-typical development. Outcome categorization, based on
130 a previously published algorithm using the Autism Diagnostic Observation Schedule (ADOS)
131 and the Mullen Scales of Early Learning (MSEL) (Ozonoff et al. 2014), has been described in
132 these cohorts previously (Mordaunt et al. 2019; Philippat et al. 2018). In brief, the typical
133 development group did not meet diagnostic criteria for ASD. Those that did not meet diagnostic
134 criteria, but had ADOS scores within three points of the cutoff or MSEL scores 1.5 to 2 standard
135 deviations below average, were categorized in the non-typical development group. Finally,
136 those who met diagnostic DSM-5 criteria and ADOS scores over the cutoff were categorized in
137 the ASD group.

138

139 *Exposure assessment*

140 Maternal urine samples collected at two time points during pregnancy (earliest timepoint
141 approximately mean 19 weeks of pregnancy, latest timepoint approximately mean 32 weeks
142 pregnancy) had urinary concentrations of a panel of metals measured using inductively coupled
143 plasma mass spectrometry by NSF International (Centers for Disease Control and Prevention
144 method 3018.3, with modifications for the expanded metals panel and the Thermo Scientific
145 iCAP RQ instrument). Metals measured include antimony, arsenic, barium, beryllium, cadmium,
146 cesium, chromium, cobalt, copper, lead, manganese, mercury, molybdenum, nickel, platinum,
147 selenium, thallium, tin, tungsten, uranium, vanadium, and zinc. Samples for both cohorts were
148 randomized together into two laboratory runs and runs had variable limits of detection (LOD)
149 (**Supplemental Table 1**). For example, for lead the LOD was either 0.1 ppb (83 samples in
150 EARLI, 36 samples in MARBLES) or 0.2 ppb (262 samples in EARLI, 369 samples in
151 MARBLES), depending on batch. To assess urinary dilution, specific gravity was measured by
152 NSF International using an ATAGO handheld digital refractometer model PAL-10S. After
153 excluding samples involved in a multiple birth (n=23), related siblings from non-multiple births
154 (selecting one randomly to keep, n=18 samples dropped), or missing gestational age at
155 collection (n=3), EARLI had 165 mothers with metals measures from two timepoints, and 15
156 mothers with a measure from one timepoint. MARBLES had 154 mothers with metals measures
157 from two timepoints, and 97 mothers with a measure from one timepoint. Distribution of
158 gestational age at urine sample collection are shown in **Supplemental Figure 1**.

159 As a sensitivity analysis, maternal blood concentrations during pregnancy of cadmium,
160 manganese, lead, selenium, and total mercury were also measured in EARLI. Maternal venous
161 blood samples were collected in trace metal free EDTA tubes. Blood samples from the first
162 study visit (n=215) were used. Metal concentrations in maternal blood samples were measured
163 by inductively coupled dynamic reaction cell plasma mass spectrometry by the US Centers for
164 Disease Control and Prevention (ELAN DRC II, PerkinElmer Norwalk, CT) (method DLS 3016.8,

165 Centers for Disease Control and Prevention). Micro-clotting of the archived blood prevented
166 measures in half of samples, leaving n=104 with measured concentrations.

167 Data used in this manuscript is publicly available through the National Institute of Mental
168 Health Data Archive (EARLI cohort repository: 1600, MARBLES cohort repository: 1946,
169 EARLI/MARBLES metals repository: 2462) and through data requests to the Principal
170 Investigators of cohorts (EARLI: MDF, MARBLES: RJS).

171

172 *Statistical analyses*

173 We used R statistical software (version 4.0.2) for statistical analysis. Code to produce
174 analyses is available (<https://github.com/bakulskilab>). Metals with less than approximately 10%
175 of samples above the LOD were dropped from analysis (beryllium, platinum, tungsten, uranium,
176 vanadium). Metals with less than 75% of samples above the LOD (antimony, cadmium,
177 chromium, lead) were treated as binary variables, based on whether a sample was above or
178 below the LOD. For the rest of the metals, concentrations were used as continuous variables.
179 We substituted all urinary metals measures quantitated with values below the LOD with the
180 value of the LOD/square root of two (Hornung and Reed 1990). Metal concentrations were
181 adjusted for specific gravity by multiplying concentrations by the ratio of [the median specific
182 gravity – 1] and [sample specific gravity – 1] (Middleton et al. 2019). We then log₂ transformed
183 the continuous concentrations. Outlier metals concentrations >5 standard deviations from the
184 mean were dropped from analyses. The number of samples dropped per metal are listed in

185 **Supplemental Table 2.**

186 We separated urinary measures into earlier and later pregnancy timepoints. For those
187 with two measures, the sample with lowest gestational age at collection was put into the earlier
188 timepoint sample. For those with only one sample, gestational age at collection \geq 28 weeks
189 (third trimester) was considered late pregnancy, and otherwise samples were considered earlier

190 pregnancy. We compared exposure levels in early and late pregnancy with Spearman
191 correlation tests.

192 We calculated univariate descriptive statistics on each cohort using mean and standard
193 deviation for continuous variables and count and frequency for categorical variables. The
194 distributions of metal concentrations were described using mean, median, standard deviation,
195 interquartile range, and the number and percent above the limit of detection. We calculated
196 Spearman correlation of metals concentrations within each cohort. Separately for each cohort,
197 we compared the bivariate sample characteristics by neurodevelopmental outcome (ASD, non-
198 typically developing, typically developing) using ANOVA tests for continuous variables and chi-
199 square tests for categorical variables.

200 To estimate the adjusted associations between urinary metals concentration in
201 pregnancy and neurodevelopmental status, we used log binomial models to get estimates of
202 relative risk. Due to convergence issues, we used the delta-method normal approximations for
203 fitting models using the epitools package (Muller and MacLehose 2014). We estimated the
204 association of each metal with ASD status relative to the typically developing group using the
205 \log_2 transformed concentrations, adjusting for gestational age at urine sampling, child sex,
206 maternal age, and maternal education. We also tested metals associations with non-typically
207 developing status (typically developing as reference) in separate log binomial models.

208 Models were fit separately for each cohort, then meta analyzed together using the
209 inverse variance method in the R meta package. We reported risk ratios (RR) and 95%
210 confidence intervals (95% CI) for each association and visualized the results using forest plots.
211 For metals that were modeled continuously, since concentrations were log-transformed, the
212 reported associations are for a doubling in concentration. For metals that were modeled as
213 binary, we reported the risk ratio for above versus below the limit of detection. To account for
214 multiple comparisons, we also reported false discovery rate adjusted p-values.

215 We performed several sensitivity analyses to assess the robustness of our findings.
216 Since runs for metals measures had variable limits of detection, which impacts binary
217 categorization and imputation for values below limit of detection, we ran models adjusted for
218 batch. We also performed multivariable logistic regression for each of our models to generate
219 adjusted odds ratios (OR) that may be compared to the risk ratios and to prior findings in the
220 literature. Lastly, we performed analyses on the subset of EARLI samples with maternal blood
221 metals measures available and compared the findings to the findings in urinary metals.

222

223 **Results**

224 *Sample descriptive statistics*

225 At the earliest pregnancy timepoint, urinary metal concentrations were above the limit of
226 detection in greater than 75% of the samples for 13 metals in each cohort (arsenic, barium,
227 cesium, cobalt, copper, manganese, mercury, molybdenum, nickel, selenium, thallium, tin, and
228 zinc) (**Supplemental Table 3**). In both EARLI and MARBLES, cobalt (Co) and nickel (Ni)
229 concentrations had the strongest correlation (Spearman $r=0.57$ in EARLI, $r=0.59$ in MARBLES)
230 (**Figure 1**).

231 In the earlier pregnancy timepoint there were metals concentrations available from 170
232 urine samples in EARLI (66 typically developing, 74 non-typically developing, 30 ASD) and 158
233 in MARBLES (104 typically developing, 18 non-typically developing, 36 ASD) (**Table 1**). In
234 EARLI, maternal education and child sex assigned at birth were associated with child
235 neurodevelopmental status. The typically developing group had higher levels of maternal
236 education (71.2% with college degree), compared to the non-typically developing (54.1%) and
237 ASD groups (43.3%). The typically developing and non-typically developing groups had a
238 similar proportion of males (42.4% and 47.3%) but lower proportion than the ASD group
239 (76.7%). In MARBLES, compared to the typically developing group (51.9% male), both the non-

240 typically developing group (66.7% male) and ASD (75.0% male) had higher proportion of males
241 (**Table 1**).

242 At the later pregnancy timepoint, urinary metal concentrations were above the limit of
243 detection in slightly less than 75% of the sample for manganese, mercury, and tin
244 (**Supplemental Table 4**), however they were modelled as continuous for comparability with the
245 early timepoint results. In late pregnancy, cobalt and nickel remained the strongest correlated
246 metals in MARBLES (Spearman $r=0.74$), but not in EARLI. In both cohorts, lead and copper
247 ($r=0.43$ in EARLI, $r=0.49$ in MARBLES) as well as lead and manganese ($r=0.45$ in both) were
248 correlated (**Supplemental Figure 2**).

249 At the later pregnancy timepoint, there were 171 samples with urinary metal
250 concentrations available in EARLI (65 typically developing, 75 non-typically developing, 31
251 ASD) and 231 in MARBLES (146 typically developing, 34 non-typically developing, 51 ASD)
252 (**Supplemental Table 5**). For mothers with two timepoints, correlation between the two were
253 strongest for measured cadmium ($r=0.48$ in EARLI, $r=0.42$ in MARBLES), cesium ($r=0.42$ in
254 both cohorts), mercury ($r=0.48$ in EARLI, $r=0.63$ in MARBLES), tin ($r=0.57$ in EARLI, $r=0.59$ in
255 MARBLES), and zinc ($r=0.53$ in EARLI, $r=0.47$ in MARBLES). Cross timepoint correlation was
256 weakest for antimony ($r=0.29$ in EARLI, $r=0.15$ in MARBLES) and manganese ($r=0.21$ in EARLI,
257 $r=0.12$ in MARBLES) (**Supplemental Table 6**).

258

259 *Urinary Metal Association with Autism Spectrum Disorder Status*

260 We examined associations between urinary metals in the earlier pregnancy timepoint
261 and ASD. In meta-analysis, comparing ASD to typical development, having urine cadmium
262 concentration above the limit of detection was associated with $RR=1.78$ (95% CI 1.19, 2.67)
263 times higher risk for ASD (EARLI $RR=1.92$, 95% CI 1.05, 3.51; MARBLES $RR=1.68$, 95% CI
264 0.97, 2.89). (**Figure 2, Table 2**). A doubling in arsenic was associated with lower ASD risk
265 ($RR=0.85$, 95% CI 0.76, 0.94), driven by the EARLI cohort (EARLI $RR=0.82$, 95% CI 0.73, 0.92;

266 MARBLES RR=1.01, 95% CI 0.78, 1.31). Marginal associations were observed with cesium,
267 where a doubling in urinary concentration was estimated to have RR=1.81 (95% CI 0.95, 3.42).
268 Thallium concentration doubling was marginally associated with RR=1.16 (95% CI 1.08, 1.26),
269 with stronger effect in MARBLES (RR=1.15, 95% CI 1.10, 1.32) than in EARLI (RR=1.00, 95%
270 CI 0.68, 1.48). The associations for cadmium (FDR=0.085) and arsenic (FDR=0.051) reached
271 FDR < 0.1 when adjusting for multiple comparisons. No associations were observed between
272 the remaining urinary metal concentrations and ASD status at this early pregnancy time point.

273 At the later pregnancy timepoint, we estimated the association between each metal
274 concentration and ASD. Comparing ASD to typically developing in meta-analyses, a doubling in
275 cesium was associated with RR=1.71 (95% CI 1.01, 2.9) in meta-analysis (EARLI RR=2.10,
276 95% CI 0.85, 5.22.; MARBLES RR=1.55, 95% CI 0.81, 2.95) (**Figure 2, Table 2**). A doubling in
277 thallium was associated with ASD with RR=1.16 (95% CI 1.10,1.23), though effects were
278 different between cohorts (EARLI RR=0.84, 95% CI 0.52, 1.37.; MARBLES RR=1.17, 95% CI
279 1.10, 1.24). A doubling in tin was associated with RR=1.12 (95% CI 1.01,1.24). A doubling in
280 mercury was marginally associated with RR=1.09 (95% CI 1.00, 1.20), with differences between
281 EARLI (RR=1.14, 95% CI 1.03, 1.26) and MARBLES (RR=0.91, 95% CI 0.73, 1.13). The
282 association with thallium reached FDR < 0.1. No associations were observed between the
283 remaining urinary metal concentrations and ASD status at this later pregnancy time point.

284

285 *Urinary Metal Association with Non-Typically Developing Status*

286 We repeated the adjusted regression analyses estimating the association of earlier
287 pregnancy urinary metals and non-typically developing status. Urine cadmium concentrations
288 above the LOD was associated with elevated risk of non-typical development, with RR=1.43
289 (95% CI 1.06, 1.92). (**Figure 3, Table 3**). A doubling of cesium urinary concentration was
290 marginally associated with RR=1.58 (95% CI 0.95, 2.63) times higher risk of non-typical
291 development. A marginal relationship with molybdenum was also observed, where a doubling in

292 concentration was related to RR=1.47 (95% CI 0.95, 2.28). A doubling of nickel was associated
293 with RR=1.40 (95% CI 1.01, 1.94), driven by the EARLI cohort with RR=1.55 (95% CI 1.08,
294 2.23). No associations were observed between the remaining urinary metal concentrations and
295 non-typically developing status at this early pregnancy time point.

296 We examined associations between non-typically developing and the later pregnancy
297 metals measures. Though not statistically significant, having urine cadmium concentration
298 above the limit of detection was associated with RR=1.24 (95% CI 0.95, 1.63) times higher risk
299 of non-typically developing status in meta-analysis (**Supplemental Figure 3, Table 3**). A
300 doubling of the essential metal selenium concentration was associated in meta-analysis with
301 RR=0.85 (95% CI 0.82, 0.88) times lower risk of non-typically developing status, driven by
302 precision of results in MARBLES and had opposite directions of effect by cohort (EARLI
303 RR=1.31, 95% CI 0.64, 2.69; MARBLES RR=0.85, 95% CI 0.82, 0.88). A doubling of the
304 essential metal zinc concentration was associated with RR=0.97 (95% CI 0.95, 0.98) lower risk
305 of non-typically developing status. The zinc and selenium associations reached FDR < 0.1. No
306 associations were observed between the remaining urinary metal concentrations and non-
307 typically developing status at this late pregnancy time point.

308

309 *Maternal Blood Metal Association with Neurodevelopmental Status*

310 In EARLI, 92 maternal blood samples collected during pregnancy had available
311 covariate and blood metals measures (41 typically developing, 32 non-typically developing, 19
312 ASD) (**Supplemental Table 7**). A doubling in maternal blood cadmium was marginally
313 associated with RR=1.11 (95% CI 0.96, 1.29) higher risk of ASD, and a doubling in maternal
314 blood lead was associated with RR=1.23 (95% CI 1.01, 1.54) higher risk of ASD (**Supplemental**
315 **Figure 3**). A doubling in cadmium was also associated with RR=1.10 (95% CI 1.02, 1.19) higher
316 risk of non-typical development. A doubling in maternal blood lead was associated with
317 RR=1.16 (95% CI 1.00, 1.35) higher risk of non-typical development (**Supplemental Figure 2**).

318 No associations were observed between the remaining blood metal concentrations (mercury,
319 selenium, manganese) and neurodevelopmental status.

320

321 *Sensitivity Analysis*

322 With batch as a covariate (**Supplemental Tables 8 and 9**), the cadmium association in
323 early pregnancy with ASD remained consistent where being over the limit of detection was
324 associated with RR=1.78 (95% CI 1.19, 2.65) times higher risk of ASD. The cadmium
325 associations with non-typical development also remained consistent. With batch adjustment,
326 antimony in earlier pregnancy was associated with ASD, with RR=1.58 (95% CI 1.01, 2.48). The
327 associations between cesium and ASD as well as non-typical development remained consistent
328 with slight attenuation, as did associations between earlier pregnancy molybdenum and nickel
329 with non-typical development. On the other hand, the relationships with thallium and ASD were
330 attenuated.

331 Using logistic regression models, consistency to the previous log binomial findings was
332 observed for cadmium and cesium. In general, estimates on the odds ratio scale were higher in
333 magnitude and significance for cadmium and cesium. Strength of relationships between arsenic,
334 mercury, thallium, and tin with ASD were attenuated with larger confidence intervals when using
335 logistic regression (**Supplemental Table 10**). Earlier pregnancy molybdenum and nickel
336 associations with non-typical development remained consistent in logistic regression, while
337 selenium and zinc associations with non-typical development were attenuated (**Supplemental**
338 **Table 11**). In logistic regression, earlier pregnancy lead had stronger association with non-
339 typical development, where lead over the LOD was marginally associated with OR=1.68 (95%
340 CI 0.92, 3.07).

341

342 **Discussion**

343 In these two prospective birth cohorts of siblings of children with ASD, we measured
344 maternal urinary metals levels during two timepoints in pregnancy and examined relationships
345 to ASD or non-typical development status at age 3. To our knowledge, this is the first study to
346 report associations between maternal prenatal urine heavy metal concentrations and ASD
347 diagnosis in children at 3 years of age in such cohorts. Our most consistent finding was
348 heightened risk of atypical neurodevelopment related to cadmium exposure. Although the
349 relationships were not significant in late pregnancy, the directions of effect were consistent
350 across time periods. Furthermore, similar findings were observed in the maternal blood
351 subsample. Cesium related to atypical neurodevelopment was also notable, with consistency
352 across ASD and non-typical development outcomes and timepoints, with exception of later
353 pregnancy cesium and non-typical development. Cadmium and cesium associations were also
354 the most robust to different modelling strategies. This study suggests metals exposure during
355 pregnancy may be related to risk of ASD or non-typical development status at age 3.

356 Existing studies have examined the relationship between heavy metals exposure and
357 ASD with considerable heterogeneity in exposure timing and matrices measured (Campbell et
358 al. 2021). A systematic review and meta-analysis of lead concentrations in children with ASD
359 from cross-sectional and case-control studies showed significant difference in blood lead levels
360 compared to controls, but not in urinary lead levels (Nakhaee et al. 2023). This mirrors our
361 results in maternal measures during pregnancy, where we found maternal blood lead levels
362 were associated with risk of ASD or non-typical development in offspring, but not maternal
363 urinary lead levels. The study in the Norwegian Mother, Father, and Child Cohort Study found
364 higher odds of ASD for children in the highest quartile of cadmium exposure measured in
365 maternal blood during pregnancy (Skogheim et al. 2021), matching results from the present
366 study. The same study found the highest quartile of maternal blood cesium levels had lower
367 odds of ASD compared to the lowest quartile, while in contrast our study suggests higher risk of
368 ASD with higher maternal urinary cesium. Our results for selenium were mixed, doubling of late

369 pregnancy selenium concentration was associated with lower risk of non-typical development,
370 however there were opposite effect estimates between cohorts. Selenium supplementation in an
371 animal model attenuated autism phenotype (Wu et al. 2022a), and studies measuring selenium
372 cross-sectionally in children in Saudi Arabia (El-Ansary et al. 2017) and China (Wu et al. 2022b)
373 found lower selenium levels in those with ASD. On the other hand, two-sample Mendelian
374 randomization analysis using genetic instruments of blood and blood-toenail selenium suggest
375 selenium levels are associated with increased risk of ASD (Guo et al. 2023), and in the Boston
376 Birth Cohort maternal red blood cell selenium levels measured at near delivery were associated
377 with increased odds of ASD in children (Lee et al. 2021). Considerable heterogeneity in
378 direction of association between selenium and ASD exist in our study and in the literature, along
379 with heterogeneity in timing and tissue of measurements. Our findings add to a growing body of
380 evidence of the neurodevelopmental impacts of metals exposure during pregnancy.

381 This study has several strengths. We were able to assay a wide array of metals with
382 high detection rates in two different birth cohorts, at two different timepoints. In one cohort, we
383 were also able to evaluate five metals in a different exposure matrix: maternal blood during
384 pregnancy. The longitudinal design allowed examination of exposure measures during
385 pregnancy that preceded subsequent ASD outcome 36 months after birth. The enriched risk
386 cohort design ensured all participants were clinically assessed using gold standards for ASD
387 diagnosis.

388 This study modeled metals as linear or dichotomous, but some metals, especially
389 essential nutrients, may have non-linear relationships. While the sibling cohort design allowed
390 for an extensively phenotyped sample, our findings may not be generalizable to populations
391 where ASD is less common, thus it would be important to also compare to results found in
392 population-based samples. Future studies should also consider other exposure matrices or
393 timepoints. The choice of exposure matrix is also important for exposure timing. For example,
394 blood cadmium levels reflect recent exposure, while urinary cadmium reflects a longer,

395 cumulative exposure (Agency for Toxic Substances and Disease Registry (ATSDR) 2012).
396 Certain exposure matrices may be more reliable for some metals. For example, blood lead is a
397 more reliable measure of recent exposure compared to urinary or hair lead levels (Agency for
398 Toxic Substances and Disease Registry (ATSDR) 2020), which may explain our findings of
399 stronger blood lead ASD associations than those seen with urinary lead.

400 This study suggests that prenatal exposure to toxic metals, such as cadmium, impacts
401 risk of ASD or non-typical development in offspring. Potential routes of exposure to metals
402 include contamination of soil and water, through ambient air, and through use in industrial
403 applications or domestic products (Tchounwou et al. 2012). Public health measures to reduce
404 these exposures to heavy metals during pregnancy may be an important preventative strategy
405 for neurodevelopmental disorders, though larger longitudinal studies are needed as well as
406 studies to determine which routes of exposure are important for specific metals.

407

408 **References**

- 409
- 410 Agency for Toxic Substances and Disease Registry (ATSDR). 2012. Toxicological profile for
411 Cadmium.
- 412 Agency for Toxic Substances and Disease Registry (ATSDR). 2020. Toxicological profile for
413 Lead.
- 414 Baj J, Flieger W, Flieger M, Forma A, Sitarz E, Skórzyńska-Dziduszko K, et al. 2021. Autism
415 spectrum disorder: Trace elements imbalances and the pathogenesis and severity of
416 autistic symptoms. *Neuroscience and Biobehavioral Reviews* 129:117–132;
417 doi:10.1016/j.neubiorev.2021.07.029.
- 418 Bölte S, Girdler S, Marschik PB. 2019. The contribution of environmental exposure to the
419 etiology of autism spectrum disorder. *Cellular and Molecular Life Sciences* 76:1275–
420 1297; doi:10.1007/s00018-018-2988-4.
- 421 Cakir J, Frye RE, Walker SJ. 2020. The lifetime social cost of autism: 1990–2029. *Research in*
422 *Autism Spectrum Disorders* 72:1–18; doi:10.1016/j.rasd.2019.101502.
- 423 Campbell KA, Hickman R, Fallin MD, Bakulski KM. 2021. Prenatal exposure to metals and
424 autism spectrum disorder: Current status and future directions. *Current Opinion in*
425 *Toxicology* 26:39–48; doi:10.1016/j.cotox.2021.04.001.
- 426 Diagnostic and statistical manual of mental disorders: DSM-5. 2013.5th ed. American
427 Psychiatric Association:Arlington, VA.
- 428 Ding M, Shi S, Qie S, Li J, Xi X. 2023. Association between heavy metals exposure (cadmium,
429 lead, arsenic, mercury) and child autistic disorder: a systematic review and meta-
430 analysis. *Front Pediatr* 11:1169733; doi:10.3389/fped.2023.1169733.
- 431 Doherty BT, Romano ME, Gui J, Punshon T, Jackson BP, Karagas MR, et al. 2020.
432 Periconceptual and prenatal exposure to metal mixtures in relation to behavioral
433 development at 3 years of age. *Environmental Epidemiology* 4;
434 doi:10.1097/EE9.000000000000106.
- 435 El-Ansary A, Bjørklund G, Tinkov AA, Skalny AV, Al Dera H. 2017. Relationship between
436 selenium, lead, and mercury in red blood cells of Saudi autistic children. *Metab Brain Dis*
437 32:1073–1080; doi:10.1007/s11011-017-9996-1.
- 438 Estes ML, McAllister AK. 2016. Maternal immune activation: Implications for neuropsychiatric
439 disorders. *Science* 353:772–777; doi:10.1126/science.aag3194.
- 440 Fruh V, Rifas-Shiman SL, Amarasiwardena C, Cardenas A, Bellinger DC, Wise LA, et al. 2019.
441 Prenatal lead exposure and childhood executive function and behavioral difficulties in
442 project viva. *NeuroToxicology* 75:105–115; doi:10.1016/j.neuro.2019.09.006.
- 443 Guo X, Tang P, Hou C, Li R. 2023. Mendelian randomization investigation highlights different
444 roles of selenium status in mental disorders. *Prog Neuropsychopharmacol Biol*
445 *Psychiatry* 122:110694; doi:10.1016/j.pnpbp.2022.110694.

- 446 Hansen SN, Schendel DE, Francis RW, Windham GC, Bresnahan M, Levine SZ, et al. 2019.
447 Recurrence risk of autism in siblings and cousins: a multi-national, population-based
448 study. *J Am Acad Child Adolesc Psychiatry* 58:866–875; doi:10.1016/j.jaac.2018.11.017.
- 449 Hansen SN, Schendel DE, Parner ET. 2015. Explaining the increase in the prevalence of autism
450 spectrum disorders: The proportion attributable to changes in reporting practices. *JAMA*
451 *Pediatrics* 169:56–62; doi:10.1001/jamapediatrics.2014.1893.
- 452 Hertz -Picciotto Irva, Schmidt RJ, Walker CK, Bennett DH, Oliver M, Shedd -Wise Kristine M., et
453 al. A Prospective Study of Environmental Exposures and Early Biomarkers in Autism
454 Spectrum Disorder: Design, Protocols, and Preliminary Data from the MARBLES Study.
455 *Environmental Health Perspectives* 126:117004; doi:10.1289/EHP535.
- 456 Heyer DB, Meredith RM. 2017. Environmental toxicology: Sensitive periods of development and
457 neurodevelopmental disorders. *NeuroToxicology* 58:23–41;
458 doi:10.1016/j.neuro.2016.10.017.
- 459 Hornung RW, Reed LD. 1990. Estimation of Average Concentration in the Presence of
460 Nondetectable Values. *Applied Occupational and Environmental Hygiene* 5:46–51;
461 doi:10.1080/1047322X.1990.10389587.
- 462 Jafari T, Rostampour N, Fallah AA, Hesami A. 2017. The association between mercury levels
463 and autism spectrum disorders: A systematic review and meta-analysis. *Journal of Trace*
464 *Elements in Medicine and Biology* 44:289–297; doi:10.1016/j.jtemb.2017.09.002.
- 465 Jedynak P, Maitre L, Guxens M, Gützkow KB, Julvez J, López-Vicente M, et al. 2021. Prenatal
466 exposure to a wide range of environmental chemicals and child behaviour between 3
467 and 7 years of age – An exposome-based approach in 5 European cohorts. *Science of*
468 *the Total Environment* 763; doi:10.1016/j.scitotenv.2020.144115.
- 469 Keyes KM, Susser E, Cheslack-postava K, Fountain C, Liu K, Bearman PS. 2012. Cohort
470 effects explain the increase in autism diagnosis among children born from 1992 to 2003
471 in california. *International Journal of Epidemiology* 41:495–503; doi:10.1093/ije/dyr193.
- 472 Lee ASE, Ji Y, Raghavan R, Wang G, Hong X, Pearson C, et al. 2021. Maternal prenatal
473 selenium levels and child risk of neurodevelopmental disorders: A prospective birth
474 cohort study. *Autism Res* 14:2533–2543; doi:10.1002/aur.2617.
- 475 Lyall K, Schmidt RJ, Hertz-Picciotto I. 2014. Maternal lifestyle and environmental risk factors for
476 autism spectrum disorders. *International Journal of Epidemiology* 43:443–464;
477 doi:10.1093/ije/dyt282.
- 478 Maenner MJ, Warren Z, Williams AR, Amoakohene E, Bakian AV, Bilder DA, et al. 2023.
479 Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8
480 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United
481 States, 2020. *MMWR Surveill Summ* 72:1–14; doi:10.15585/mmwr.ss7202a1.
- 482 Martin EM, Fry RC. 2018. Environmental Influences on the Epigenome: Exposure- Associated
483 DNA Methylation in Human Populations. *Annual Review of Public Health* 39:309–333;
484 doi:10.1146/annurev-publhealth-040617-014629.

- 485 Middleton DRS, Watts MJ, Polya DA. 2019. A comparative assessment of dilution correction
486 methods for spot urinary analyte concentrations in a UK population exposed to arsenic in
487 drinking water. *Environment International* 130:104721; doi:10.1016/j.envint.2019.03.069.
- 488 Miller M, Musser ED, Young GS, Olson B, Steiner RD, Nigg JT. 2019. Sibling Recurrence Risk
489 and Cross-aggregation of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum
490 Disorder. *JAMA Pediatr* 173:147–152; doi:10.1001/jamapediatrics.2018.4076.
- 491 Mordaunt CE, Park BY, Bakulski KM, Feinberg JI, Croen LA, Ladd-Acosta C, et al. 2019. A
492 meta-analysis of two high-risk prospective cohort studies reveals autism-specific
493 transcriptional changes to chromatin, autoimmune, and environmental response genes
494 in umbilical cord blood. *Mol Autism* 10:36; doi:10.1186/s13229-019-0287-z.
- 495 Muller CJ, MacLehose RF. 2014. Estimating predicted probabilities from logistic regression:
496 different methods correspond to different target populations. *International Journal of*
497 *Epidemiology* 43:962–970; doi:10.1093/ije/dyu029.
- 498 Nakhaee S, Amirabadizadeh A, Farnia V, Ali Azadi N, Mansouri B, Radmehr F. 2023.
499 Association Between Biological Lead Concentrations and Autism Spectrum Disorder
500 (ASD) in Children: a Systematic Review and Meta-Analysis. *Biol Trace Elem Res*
501 201:1567–1581; doi:10.1007/s12011-022-03265-9.
- 502 Newschaffer CJ, Croen LA, Fallin MD, Hertz-Picciotto I, Nguyen DV, Lee NL, et al. 2012. Infant
503 siblings and the investigation of autism risk factors. *Journal of Neurodevelopmental*
504 *Disorders* 4:7; doi:10.1186/1866-1955-4-7.
- 505 Ozonoff S, Young GS, Belding A, Hill M, Hill A, Hutman T, et al. 2014. The Broader Autism
506 Phenotype in Infancy: When Does It Emerge? *J Am Acad Child Adolesc Psychiatry*
507 53:398-407.e2; doi:10.1016/j.jaac.2013.12.020.
- 508 Philippat C, Barkoski J, Tancredi DJ, Elms B, Barr D, Ozonoff S, et al. 2018. Prenatal exposure
509 to organophosphate pesticides and risk of autism spectrum disorders and other non-
510 typical development at 3 years in a high-risk cohort. *Int J Hyg Environ Health* 221:548–
511 555; doi:10.1016/j.ijheh.2018.02.004.
- 512 Rashaid AHB, Nusair SD, Alqhazo MT, Adams JB, Abu-Dalo MA, Bashtawi MA. 2021. Heavy
513 metals and trace elements in scalp hair samples of children with severe autism spectrum
514 disorder: A case-control study on Jordanian children. *Journal of Trace Elements in*
515 *Medicine and Biology* 67; doi:10.1016/j.jtemb.2021.126790.
- 516 Rogge N, Janssen J. 2019. The Economic Costs of Autism Spectrum Disorder: A Literature
517 Review. *Journal of Autism and Developmental Disorders* 49:2873–2900;
518 doi:10.1007/s10803-019-04014-z.
- 519 Saghazadeh A, Rezaei N. 2017. Systematic review and meta-analysis links autism and toxic
520 metals and highlights the impact of country development status: Higher blood and
521 erythrocyte levels for mercury and lead, and higher hair antimony, cadmium, lead, and
522 mercury. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 79:340–
523 368; doi:10.1016/j.pnpbp.2017.07.011.

- 524 Skogheim TS, Weyde KVF, Engel SM, Aase H, Surén P, Øie MG, et al. 2021. Metal and
525 essential element concentrations during pregnancy and associations with autism
526 spectrum disorder and attention-deficit/hyperactivity disorder in children. *Environment*
527 *International* 152; doi:10.1016/j.envint.2021.106468.
- 528 Tchounwou PB, Yedjou CG, Patlolla AK, Sutton DJ. 2012. Heavy Metals Toxicity and the
529 Environment. *EXS* 101:133–164; doi:10.1007/978-3-7643-8340-4_6.
- 530 Watson CV, Lewin M, Ragin-Wilson A, Jones R, Jarrett JM, Wallon K, et al. 2020.
531 Characterization of trace elements exposure in pregnant women in the United States,
532 NHANES 1999–2016. *Environmental Research* 183; doi:10.1016/j.envres.2020.109208.
- 533 Worley JA, Matson JL, Sipes M, Kozlowski AM. 2011. Prevalence of autism spectrum disorders
534 in toddlers receiving early intervention services. *Research in Autism Spectrum Disorders*
535 5:920–925; doi:10.1016/j.rasd.2010.10.007.
- 536 Wu H, Zhao G, Liu S, Zhang Q, Wang P, Cao Y, et al. 2022a. Supplementation with selenium
537 attenuates autism-like behaviors and improves oxidative stress, inflammation and
538 related gene expression in an autism disease model. *J Nutr Biochem* 107:109034;
539 doi:10.1016/j.jnutbio.2022.109034.
- 540 Wu J, Wang D, Yan L, Jia M, Zhang J, Han S, et al. 2022b. Associations of essential element
541 serum concentrations with autism spectrum disorder. *Environ Sci Pollut Res Int*
542 29:88962–88971; doi:10.1007/s11356-022-21978-1.
- 543 Zhang J, Li X, Shen L, Ullah N, Zhang X, Chen L, et al. 2021. Journal of Trace Elements in
544 Medicine and Biology Trace elements in children with autism spectrum disorder□: A
545 meta-analysis based on case-control studies. 67.
- 546
547

Table 1. Maternal and child characteristics of participants in the primary analytic sample with measures of metal exposure in urine from early pregnancy. Data are split by cohort and compared by neurodevelopmental status of the sibling. Distributions of categorical variables are compared with a chi-square test and continuous variables are compared with ANOVA test.

EARLI cohort	Typically developing N=66	Non-typically developing N=74	Autism spectrum disorder N=30	P-value
Maternal Education				0.020
College Degree	47 (71.2%)	40 (54.1%)	13 (43.3%)	
No Degree	19 (28.8%)	34 (45.9%)	17 (56.7%)	
Maternal Age	35.1 (4.68)	33.3 (4.52)	33.8 (3.87)	0.057
Infant Sex				0.006
F	38 (57.6%)	39 (52.7%)	7 (23.3%)	
M	28 (42.4%)	35 (47.3%)	23 (76.7%)	
Weeks of Gestation at Sample Collection	19.1 (5.14)	18.3 (6.44)	19.4 (7.76)	0.607
Infant Gestational Age at Birth	39.5 (1.40)	39.5 (1.36)	38.9 (2.00)	0.094
MARBLES cohort	Typically developing N=104	Non-typically developing N=18	Autism spectrum disorder N=36	P-value
Maternal Education				0.259
College Degree	62 (59.6%)	9 (50.0%)	16 (44.4%)	
No Degree	42 (40.4%)	9 (50.0%)	20 (55.6%)	
Maternal Age	34.6 (4.73)	33.8 (4.71)	34.6 (5.01)	0.822
Infant Sex				0.041
Female	50 (48.1%)	6 (33.3%)	9 (25.0%)	
Male	54 (51.9%)	12 (66.7%)	27 (75.0%)	
Weeks of Gestation at Sample Collection	19.3 (3.99)	18.7 (3.99)	19.0 (3.98)	0.803
Infant Gestational Age at Birth	38.9 (1.39)	38.9 (1.54)	39.3 (1.04)	0.296

Acronyms: Early Autism Risk Longitudinal Investigation (EARLI), Markers of Autism Risk in Babies-Learning Early Signs (MARBLES)

Table 2. Adjusted risk ratios for the associations between maternal urinary metal concentrations measured during pregnancy and risk of autism spectrum disorder, relative to typically developing. Log binomial models were adjusted for gestational age, child sex, maternal age, and maternal education. Four metals were modeled categorically (above versus below the limit of detection) and the remaining metals were log₂ transformed and modeled continuously.

Metal	Time	EARLI			MARBLEs			Meta-Analysis			
		RR	CI	P	RR	CI	P	RR	CI	P	FDR
Modeled categorically											
Antimony	Early	1.10	(0.59,2.07)	0.76	1.25	(0.63,2.46)	0.52	1.17	(0.74,1.85)	0.51	0.67
	Late	1.08	(0.59,1.97)	0.81	1.21	(0.66,2.20)	0.54	1.14	(0.75,1.75)	0.54	0.88
Cadmium	Early**	1.92	(1.05,3.51)	0.034	1.68	(0.97,2.89)	0.062	1.78	(1.19,2.67)	0.005	0.085
	Late	1.55	(0.91,2.64)	0.11	0.97	(0.56,1.68)	0.90	1.23	(0.84,1.81)	0.28	0.79
Chromium	Early	1.34	(0.76,2.39)	0.31	1.35	(0.71,2.56)	0.37	1.34	(0.88,2.06)	0.18	0.45
	Late	1.43	(0.81,2.51)	0.22	0.92	(0.42,2.03)	0.84	1.23	(0.78,1.95)	0.38	0.88
Lead	Early	1.73	(0.90,3.33)	0.10	1.09	(0.61,1.93)	0.78	1.33	(0.86,2.05)	0.20	0.45
	Late	1.64	(0.87,3.08)	0.13	1.08	(0.67,1.73)	0.75	1.25	(0.86,1.83)	0.24	0.74
Modeled continuously											
Arsenic	Early**	0.82	(0.73,0.92)	<0.001	1.01	(0.78,1.31)	0.93	0.85	(0.76,0.94)	0.0015	0.051
	Late	1.15	(0.91,1.46)	0.24	1.10	(0.89,1.36)	0.39	1.12	(0.96,1.32)	0.15	0.60
Barium	Early	1.19	(0.91,1.56)	0.20	1.07	(0.84,1.36)	0.58	1.12	(0.94,1.34)	0.20	0.45
	Late	0.98	(0.81,1.19)	0.85	0.99	(0.83,1.16)	0.86	0.98	(0.87,1.11)	0.80	0.92
Cesium	Early*	2.37	(0.80,7.04)	0.12	1.56	(0.71,3.44)	0.27	1.81	(0.95,3.42)	0.069	0.35
	Late**	2.10	(0.85,5.22)	0.11	1.55	(0.81,2.95)	0.19	1.71	(1.01,2.9)	0.045	0.31
Cobalt	Early	0.83	(0.51,1.34)	0.43	0.74	(0.42,1.29)	0.28	0.79	(0.55,1.13)	0.20	0.45
	Late	0.96	(0.67,1.36)	0.81	1.00	(0.73,1.36)	0.99	0.98	(0.78,1.24)	0.87	0.92
Copper	Early	1.37	(0.61,3.08)	0.45	1.09	(0.64,1.85)	0.76	1.17	(0.75,1.82)	0.50	0.67
	Late	3.55	(1.23,10.3)	0.02	0.93	(0.72,1.19)	0.55	0.99	(0.78,1.27)	0.96	0.96
Manganese	Early	0.95	(0.67,1.35)	0.79	1.05	(0.80,1.38)	0.71	1.01	(0.82,1.26)	0.90	0.96
	Late	0.94	(0.70,1.25)	0.66	1.00	(0.79,1.28)	0.97	0.98	(0.81,1.17)	0.79	0.92
Mercury	Early	1.14	(1.01,1.29)	0.039	0.82	(0.60,1.11)	0.19	1.09	(0.97,1.22)	0.16	0.45
	Late*	1.14	(1.03,1.26)	0.013	0.91	(0.73,1.13)	0.40	1.09	(1.00,1.20)	0.061	0.35
Molybdenum	Early	1.46	(0.73,2.91)	0.29	0.97	(0.68,1.38)	0.88	1.06	(0.77,1.45)	0.73	0.85
	Late	0.93	(0.79,1.10)	0.43	1.08	(0.78,1.49)	0.64	0.96	(0.83,1.12)	0.62	0.88
Nickel	Early	1.05	(0.72,1.53)	0.8	1.04	(0.57,1.88)	0.90	1.05	(0.76,1.44)	0.78	0.86
	Late	1.07	(0.72,1.60)	0.73	1.01	(0.70,1.44)	0.96	1.04	(0.79,1.35)	0.79	0.92
Selenium	Early	0.95	(0.65,1.40)	0.8	0.91	(0.75,1.10)	0.33	0.92	(0.77,1.09)	0.32	0.55
	Late	2.13	(0.69,6.55)	0.19	0.92	(0.72,1.18)	0.52	0.96	(0.75,1.22)	0.73	0.92
Thallium	Early*	1	(0.68,1.48)	0.98	1.15	(1.01,1.32)	0.038	1.14	(1.00,1.29)	0.05	0.34
	Late**	0.84	(0.52,1.37)	0.5	1.17	(1.10,1.24)	<0.001	1.16	(1.10,1.23)	<0.001	<0.001
Tin	Early	1.17	(1,1.36)	0.043	0.98	(0.77,1.24)	0.85	1.11	(0.98,1.26)	0.11	0.42

Metal	Time	EARLI			MARBLES			Meta-Analysis			
		RR	CI	P	RR	CI	P	RR	CI	P	FDR
Zinc	Late**	1.18	(1.04,1.33)	0.01	1.01	(0.84,1.22)	0.89	1.12	(1.01,1.24)	0.027	0.23
	Early	1.93	(1.01,3.70)	0.048	0.95	(0.82,1.09)	0.45	0.98	(0.85,1.13)	0.75	0.85
	Late	1.51	(0.75,3.01)	0.25	1.09	(0.81,1.48)	0.56	1.15	(0.87,1.52)	0.32	0.84

Symbols: ** meta-analysis p-value < 0.05. * meta-analysis p-value < 0.1.


Table 3. Adjusted risk ratios for the associations between maternal urinary metal concentrations measured during pregnancy and risk of non-typically developing, relative to typically developing. Log binomial models were adjusted for gestational age, child sex, maternal age, and maternal education. Four metals were modeled categorically (above versus below the limit of detection) and the remaining metals were log₂ transformed and modeled continuously.

Metal	Time	EARLI			MARBLIS			Meta-Analysis			
		RR	CI	P	RR	CI	P	RR	CI	P	FDR
Modeled categorically											
Antimony	Early	1.18	(0.85,1.64)	0.32	0.70	(0.18,2.81)	0.62	1.15	(0.84,1.58)	0.39	0.55
	Late	0.96	(0.67,1.38)	0.84	1.68	(0.85,3.35)	0.14	1.09	(0.79,1.50)	0.61	0.88
Cadmium	Early**	1.28	(0.94,1.76)	0.12	3.12	(1.34,7.3)	0.008	1.43	(1.06,1.92)	0.018	0.20
	Late	1.10	(0.81,1.49)	0.55	2.02	(1.1,3.71)	0.023	1.24	(0.95,1.63)	0.12	0.58
Chromium	Early	0.97	(0.68,1.37)	0.86	1.47	(0.54,3.99)	0.45	1.01	(0.73,1.41)	0.93	0.96
	Late	1.01	(0.67,1.51)	0.97	1.50	(0.70,3.21)	0.29	1.1	(0.77,1.58)	0.60	0.88
Lead	Early	1.11	(0.80,1.55)	0.53	2.50	(1.04,6.00)	0.041	1.23	(0.9,1.67)	0.19	0.45
	Late	0.87	(0.64,1.18)	0.36	1.09	(0.59,2.00)	0.79	0.91	(0.69,1.19)	0.49	0.88
Modeled continuously											
Arsenic	Early	1.10	(0.95,1.28)	0.19	0.87	(0.60,1.27)	0.48	1.07	(0.93,1.23)	0.33	0.55
	Late	1.08	(0.93,1.25)	0.34	0.81	(0.68,0.97)	0.025	0.96	(0.86,1.08)	0.49	0.88
Barium	Early	1.00	(0.88,1.13)	0.99	1.04	(0.7,1.53)	0.85	1.00	(0.89,1.13)	0.96	0.96
	Late	0.97	(0.87,1.07)	0.53	0.96	(0.77,1.2)	0.74	0.97	(0.88,1.06)	0.48	0.88
Cesium	Early*	1.63	(0.90,2.96)	0.11	1.44	(0.53,3.87)	0.47	1.58	(0.95,2.63)	0.079	0.35
	Late	1.07	(0.82,1.39)	0.63	1.06	(0.55,2.03)	0.86	1.07	(0.84,1.36)	0.61	0.88
Cobalt	Early	1.09	(0.91,1.30)	0.34	1.06	(0.51,2.19)	0.88	1.09	(0.92,1.29)	0.33	0.55
	Late	0.9	(0.72,1.12)	0.33	0.77	(0.50,1.18)	0.23	0.87	(0.71,1.06)	0.16	0.60
Copper	Early	1.19	(0.74,1.91)	0.47	1.33	(0.54,3.28)	0.53	1.22	(0.80,1.85)	0.35	0.55
	Late	1.01	(0.78,1.29)	0.97	0.87	(0.65,1.17)	0.35	0.95	(0.78,1.14)	0.57	0.88
Manganese	Early	0.88	(0.69,1.13)	0.32	1.01	(0.64,1.58)	0.98	0.91	(0.73,1.13)	0.39	0.55
	Late	0.92	(0.77,1.11)	0.39	1.05	(0.79,1.40)	0.74	0.96	(0.82,1.11)	0.58	0.88
Mercury	Early	1.04	(0.95,1.14)	0.40	0.76	(0.49,1.19)	0.23	1.03	(0.94,1.12)	0.57	0.72
	Late	1.03	(0.93,1.14)	0.54	0.83	(0.61,1.12)	0.22	1.01	(0.92,1.11)	0.84	0.92
Molybdenum	Early*	1.54	(0.91,2.59)	0.10	1.32	(0.59,2.95)	0.49	1.47	(0.95,2.28)	0.083	0.35
	Late	1.04	(0.82,1.33)	0.72	0.93	(0.71,1.22)	0.62	0.99	(0.83,1.19)	0.95	0.96
Nickel	Early**	1.55	(1.08,2.23)	0.018	0.92	(0.44,1.93)	0.82	1.40	(1.01,1.94)	0.043	0.34
	Late	1.23	(0.91,1.66)	0.19	0.74	(0.59,0.94)	0.012	0.89	(0.74,1.07)	0.23	0.74
Selenium	Early	1.38	(0.76,2.51)	0.29	1.13	(0.53,2.43)	0.75	1.28	(0.80,2.05)	0.30	0.55
	Late**	1.31	(0.64,2.69)	0.46	0.85	(0.82,0.88)	<0.001	0.85	(0.82,0.88)	<0.001	<0.001
Thallium	Early	0.71	(0.41,1.23)	0.22	0.96	(0.56,1.66)	0.89	0.83	(0.56,1.22)	0.34	0.55
	Late	1.01	(0.87,1.19)	0.87	1.02	(0.71,1.47)	0.92	1.01	(0.88,1.17)	0.85	0.92
Tin	Early	1.05	(0.96,1.16)	0.27	0.83	(0.54,1.3)	0.42	1.04	(0.95,1.14)	0.36	0.55

Metal	Time	EARLI			MARBLER			Meta-Analysis			
		RR	CI	P	RR	CI	P	RR	CI	P	FDR
Zinc	Late	1.03	(0.94,1.13)	0.52	0.84	(0.63,1.13)	0.26	1.01	(0.93,1.11)	0.78	0.92
	Early	0.98	(0.88,1.09)	0.73	0.96	(0.67,1.36)	0.80	0.98	(0.88,1.08)	0.69	0.84
	Late**	0.97	(0.95,0.98)	<0.001	0.92	(0.82,1.03)	0.14	0.97	(0.95,0.98)	<0.001	<0.001

Symbols: ** meta-analysis p-value < 0.05. * meta-analysis p-value < 0.1.

Figure 1. Spearman correlations of urinary metals concentrations, measured during early pregnancy, stratified by cohort. The upper right triangle shows the EARLI cohort. The lower left triangle shows the MARBLES cohort. Metals are represented by their chemical symbol along the diagonal.



Acronyms: *Early Autism Risk Longitudinal Investigation (EARLI)*, *Markers of Autism Risk in Babies-Learning Early Signs (MARBLES)*,

Figure 2. Adjusted risk ratios for the associations between maternal urinary metals concentrations measuring during pregnancy and risk of autism spectrum disorder, relative to typically developing. Antimony, cadmium, chromium, and lead compare over limit of detection vs under the limit of detection for that metal. Remaining metals show the risk ratio for a doubling in metal concentration. Analyses were performed stratified by cohort (EARLI and MARBLES) and then meta-analyzed across cohorts. Red denotes a nominal meta-analysis p-value < 0.05, and orange a nominal meta-analysis p-value < 0.10.




Figure 3. Adjusted risk ratios for the associations between maternal urinary metals concentrations measuring during pregnancy and risk of non-typically developing, relative to typically developing. Antimony, cadmium, chromium, and lead compare over limit of detection vs under the limit of detection for that metal. Remaining metals show risk ratio for a doubling in metal concentration. Analyses were performed stratified by cohort (EARLI and MARBLES) and then meta-analyzed across cohorts. Red denotes a nominal meta-analysis p-value < 0.05, and orange a nominal meta-analysis p-value < 0.10.

